Compare IAUX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAUX | TSHA |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | IAUX | TSHA |
|---|---|---|
| Price | $1.76 | $4.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $1.50 | ★ $11.63 |
| AVG Volume (30 Days) | ★ 8.0M | 2.6M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | $9,773,000.00 |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 89.12 | 17.28 |
| 52 Week Low | $0.89 | $3.10 |
| 52 Week High | $2.24 | $7.30 |
| Indicator | IAUX | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 30.23 |
| Support Level | $1.59 | $4.37 |
| Resistance Level | $1.95 | $5.07 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 51.92 | 8.15 |
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.